Amgen (AMGN) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Amgen, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track AMGN live on Mooboard →

Next 30 days1

  • Aug 19, 2026
    Amgen(AMGN)Phase 2/3 readout
    Dazodalibep · Phase 3 · Sjogren's Syndrome
    NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity. Primary completion 2026-08-19 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days2

  • Oct 22, 2026
    Amgen(AMGN)Phase 2/3 readout
    Dazodalibep · Phase 3 · Sjögren's Syndrome (SS)
    NCT06245408: A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State. Primary completion 2026-10-22 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 31, 2026
    Amgen(AMGN)Phase 2/3 readout
    anvumetostat · Phase 2 · MTAP-deleted NSCLC
    NCT06593522: A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201). Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later22

  • Nov 30, 2026
    Amgen(AMGN)Phase 2/3 readout
    Anvumetostat · Phase 1 / Phase 2 · Advanced MTAP-null Solid Tumors
    NCT05094336: A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101). Primary completion 2026-11-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 14, 2026
    Amgen(AMGN)Phase 2/3 readout
    ABP 234 · Phase 3 · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
    NCT06430866: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab). Primary completion 2026-12-14 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 21, 2027
    Amgen(AMGN)Phase 2/3 readout
    Maridebart cafraglutide · Phase 3 · Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
    NCT06858878: Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight. Primary completion 2027-01-21 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 21, 2027
    Amgen(AMGN)Phase 2/3 readout
    Maridebart Cafraglutide · Phase 3 · Obesity
    NCT06858839: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight. Primary completion 2027-01-21 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 22, 2027
    Amgen(AMGN)Phase 2/3 readout
    AMG 732 · Phase 1 / Phase 2 · Thyroid Eye Disease
    NCT06401044: A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease. Primary completion 2027-02-22 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 13, 2027
    Amgen(AMGN)Phase 2/3 readout
    Inebilizumab · Phase 2 · Neuromyelitis Optica Spectrum Disorder
    NCT05549258: Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder. Primary completion 2027-04-13 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 19, 2027
    Amgen(AMGN)Phase 2/3 readout
    Ocrelizumab (US) · Phase 3 · Relapsing-remitting Multiple Sclerosis (RRMS)
    NCT06700343: Comparison Between ABP 692 and Ocrevus® (Ocrelizumab). Primary completion 2027-04-19 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 27, 2027
    Amgen(AMGN)Phase 2/3 readout
    Maridebart cafraglutide · Phase 3 · Obesity Disease
    NCT06987695: Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease. Primary completion 2027-04-27 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 4, 2027
    Amgen(AMGN)Phase 2/3 readout
    Romosozumab · Phase 3 · Osteogenesis Imperfecta
    NCT05972551: Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta. Primary completion 2027-05-04 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Amgen(AMGN)Phase 2/3 readout
    Sotorasib · Phase 3 · Non-Small Cell Lung Cancer (NSCLC)
    NCT05920356: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202). Primary completion 2027-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Amgen(AMGN)Phase 2/3 readout
    Etelcalcetide · Phase 3 · Secondary Hyperparathyroidism
    NCT03969329: A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis. Primary completion 2027-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 5, 2027
    Amgen(AMGN)Phase 2/3 readout
    Tarlatamab · Phase 3 · Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer
    NCT06211036: Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab. Primary completion 2027-07-05 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 18, 2027
    Amgen(AMGN)Phase 2/3 readout
    Avacopan · Phase 3 · Vasculitis
    NCT06321601: Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.. Primary completion 2027-07-18 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 31, 2027
    Amgen(AMGN)Phase 2/3 readout
    ABP 938 8 mg · Phase 3 · Neovascular Age-related Macular Degeneration; nAMD
    NCT07614776: A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration. Primary completion 2027-07-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 29, 2027
    Amgen(AMGN)Phase 2/3 readout
    Maridebart cafraglutide · Phase 3 · Obstructive Sleep Apnea
    NCT07226765: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy. Primary completion 2027-09-29 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 29, 2027
    Amgen(AMGN)Phase 2/3 readout
    Maridebart cafraglutide · Phase 3 · Obesity; Obstructive Sleep Apnea
    NCT07225686: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy. Primary completion 2027-09-29 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 29, 2027
    Amgen(AMGN)Phase 2/3 readout
    Maridebart cafraglutide · Phase 2 · Overweight or Obesity and Elevated Liver Fat
    NCT07441252: A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight. Primary completion 2027-09-29 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 24, 2027
    Amgen(AMGN)Phase 2/3 readout
    Blinatumomab · Phase 1 / Phase 2 · B Cell Precursor Acute Lymphoblastic Leukemia
    NCT04521231: A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL. Primary completion 2027-11-24 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 26, 2027
    Amgen(AMGN)Phase 2/3 readout
    Maridebart Cafraglutide · Phase 3 · Obesity; Overweight
    NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION). Primary completion 2027-12-26 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 26, 2027
    Amgen(AMGN)Phase 2/3 readout
    Maridebart cafraglutide · Phase 3 · Obesity; Overweight
    NCT07684235: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION). Primary completion 2027-12-26 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 30, 2027
    Amgen(AMGN)Phase 2/3 readout
    Tarlatamab · Phase 2 · Relapsed/Refractory Small Cell Lung Cancer
    NCT05060016: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC). Primary completion 2027-12-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 3, 2028
    Amgen(AMGN)Phase 2/3 readout
    Maridebart Cafraglutide · Phase 3 · Obesity or Overweight
    NCT07575399: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH). Primary completion 2028-01-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Amgen has moved — past-year price reactions

How binary is AMGN? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

0.8%
typical day (1Y)
0
±10% days
27.4%
annualized vol
250
trading days
Largest single-day moves
  • +8.2%2026-02-04no matched headline
  • +7.8%2025-11-05no matched headline
  • +5.8%2025-10-01no matched headline
  • +4.8%2026-06-11no matched headline
  • -4.7%2026-05-01no matched headline
  • +4.6%2025-11-11no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Amgen — active clinical pipeline

Amgen's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

39 assets87 programsPh1 24Ph2 16Ph3 41· 6 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicNeuroscienceCardiovascularInfectiousOphthalmologyOther
Maridebart CafraglutideMetabolic
Phase 1
OverweightType 2 Diabetes Mellitus
Phase 2
Overweight or Obesity and Elevated Liver FatType 2 Diabetes Mellitus (T2DM)
Phase 3
Atherosclerotic Cardiovascular DiseaseHeart Failure With Preserved Ejection FractionObesity (4)Obesity DiseaseObesity or OverweightObstructive Sleep ApneaType 2 Diabetes Mellitus (T2DM), Obesity, Overweight
TarlatamabOncology · DLL3×CD3
Phase 1
Extensive Stage Small Cell Lung Cancer (3)Small Cell Lung Carcinoma
Phase 2
Extensive Stage Small Cell Lung CancerRelapsed/Refractory Small Cell Lung CancerSmall Cell Lung Cancer (SCLC)
Phase 3
Extensive-Stage Small-Cell Lung CancerLimited Stage Small Cell Lung CancerSmall Cell Lung Cancer (SCLC)Small-cell Lung Cancer
InebilizumabAutoimmune · CD19
Phase 2
Generalized Myasthenia GravisImmunoglobulin G4-related DiseaseNeuromyelitis Optica Spectrum DisorderSystemic Lupus Erythematosus
Phase 3
Autoimmune HepatitisIgG4 Related DiseaseMyasthenia Gravis
BlinatumomabOncology · CD19×CD3
Phase 2
B Cell Precursor Acute Lymphoblastic LeukemiaB Precursor Acute Lymphoblastic LeukemiaRelapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Phase 3
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
XaluritamigOncology
Phase 1
Ewing SarcomaMetastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate Cancer (2)
Phase 3
Metastatic Castration-resistant Prostate Cancer (2)
ApremilastAutoimmune · PDE4A
Phase 3
Active Juvenile Psoriatic ArthritisBehçet DiseaseBehçet's DiseasePlaque Psoriasis (2)
DazodalibepAutoimmune · CD40L
Phase 3
Sjogren's SyndromeSjögren's SyndromeSjögren's Syndrome (SS)
SotorasibOncology · KRAS
Phase 1
Advanced Solid Tumors
Phase 2
Advanced Solid Tumors
Phase 3
Non-Small Cell Lung Cancer (NSCLC)
ABP 234Oncology
Phase 3
Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerEarly-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
OlpasiranCardiovascular · LPA mRNA
Phase 3
Atherosclerotic Cardiovascular DiseaseCardiovascular Disease (2)
RomiplostimCardiovascular · TPO-R
Phase 3
Chemotherapy-induced ThrombocytopeniaPrimary Immune Thrombocytopenia
ABP 206Oncology
Phase 3
Melanoma
ABP 938 8 mgOphthalmology
Phase 3
Neovascular Age-related Macular Degeneration
AvacopanAutoimmune · C5aR
Phase 3
Vasculitis
Erenumab Dose 1Neuroscience
Phase 3
Migraine
EtelcalcetideOther · CASR
Phase 3
Secondary Hyperparathyroidism (2)
FOLFIRI RegimenOncology
Phase 3
Metastatic Colorectal Cancer
Ocrelizumab (US)Neuroscience · CD20
Phase 3
Relapsing-remitting Multiple Sclerosis (RRMS)
PegloticaseOther · Uric acid
Phase 3
Uncontrolled Gout
RomosozumabOther · SOST
Phase 3
Osteogenesis Imperfecta
TeprotumumabOther · IGF1R
Phase 3
Thyroid Eye Disease
anvumetostatOncology
Phase 1
Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersThoracic Tumors
Phase 2
Advanced MTAP-null Solid TumorsMTAP-deleted NSCLC
AMG 732Other
Phase 2
Thyroid Eye Disease (2)
AMG 691Immunology
Phase 1
AsthmaImmunology
AMG 127Metabolic
Phase 1
Diabetes Mellitus, Type 2
AMG 355Oncology
Phase 1
Advanced Solid Tumors
AMG 410Oncology
Phase 1
KRAS Altered Advanced or Metastatic Solid Tumors
AMG 436Oncology
Phase 1
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
AMG 509Oncology
Phase 1
Prostate Cancer
AMG 513Other
Phase 1
Cardiometabolic Disease
COCMetabolic
Phase 1
Overweight
Evolocumab Drug Substance AOther
Phase 1
Pharmacokinetics
Evolocumab Drug Substance A (Test)Other
Phase 1
Healthy volunteers
YL201Oncology
Phase 1
Small Cell Lung Cancer
ZL-1310Oncology
Phase 1
Small Cell Lung Cancer

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.